INMED PHARMACEUTICALS INC. Inventory Write-down
INMED PHARMACEUTICALS INC. (INM) reported Inventory Write-down of $70.00 thousand for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. inventory write-down for the quarter ending 2025-12-31 was $70.00K.
- INMED PHARMACEUTICALS INC. inventory write-down for the quarter ending 2025-03-31 was $0.00.
- INMED PHARMACEUTICALS INC. inventory write-down for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- INMED PHARMACEUTICALS INC. inventory write-down for the quarter ending 2024-06-30 was $42.41K.
- INMED PHARMACEUTICALS INC. inventory write-down for fiscal 2023 was $308.94K.
| Period end | Inventory Write-down | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $208.74K 10-Q · filed 2026-02-11 | $70.00K 10-Q · filed 2026-02-11 | $70.00K 10-Q · filed 2026-02-11 | ||
| 2025-09-30 | $208.74K 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $208.74K 10-Q · filed 2026-02-11 | $0.00 S-4 · filed 2026-07-02 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | $42.41K derived: sum of 2 quarters · filed 2026-07-02 | $42.41K derived: sum of 3 quarters · filed 2026-07-02 | $212.88K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-06-30 | $42.41K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $42.41K derived: sum of 2 quarters · filed 2026-07-02 | $212.88K derived: sum of 3 quarters · filed 2026-07-02 | $305.81K S-4 · filed 2026-07-02 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $170.47K derived: sum of 2 quarters · filed 2025-05-12 | $263.40K 10-Q · filed 2025-05-12 | -$4.43K derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $170.47K 10-Q · filed 2025-02-12 | $263.40K 10-Q · filed 2025-02-12 | -$4.43K derived: sum of 3 quarters · filed 2025-02-12 | -$4.43K derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-09-30 | $92.93K 10-Q · filed 2024-11-14 | -$174.91K derived: sum of 2 quarters · filed 2024-11-14 | -$174.91K derived: sum of 3 quarters · filed 2024-11-14 | -$174.91K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$267.83K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$267.83K derived: sum of 2 quarters · filed 2024-09-30 | -$267.83K derived: sum of 3 quarters · filed 2024-09-30 | $308.94K 10-K · filed 2024-09-30 | |
| 2023-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-02-13 | $576.77K 10-Q · filed 2023-05-15 | ||
| 2022-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $576.77K 10-Q · filed 2024-02-13 | |||
| 2022-09-30 | $576.77K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |